Features of upper gastrointestinal tract malignancies in Aydin region

Yıl 2015, Cilt: 23 Sayı: 3, 67 - 69, 25.12.2015

Adil Coşkun , Serkan Borazan Abdülvahit Yükselen İbrahim Meteoğlu İmran Kurt Ömürlü Mehmet Hadi Yaşa

https://doi.org/10.17940/endoskopi.468389

Cited By: 3

Öz

Background and Aims: Upper gastrointestinal tract malignancies are among the major causes of morbidity and mortality worldwide. Esophagogastroduodenoscopy is the gold standard for the diagnosis of upper gastrointestinal tract cancers. The aim of our study was to determine features of upper gastrointestinal tract malignancies including age, gender, localization, histological types and symptoms prior to the procedure in the cases that were identified by in our endoscopy unit and finally diagnosed by biopsy. Materials and Methods: A total of 209 (2.71%) of 7.688 patients who underwent esophagogastroduodenoscopy in our endoscopy unit and who were diagnosed with malignancy were included in the study. Results: Of the patients diagnosed with malignancy by esophagogastroduodenoscopy, 145 were men (69,4%) and 64 were women (30,6%). Mean age was 62.18±12.07 years. In the sample, 21.1% of malignant tumors were detected in the esophagus, 75.1% in the stomach, and 3.8% in the duodenum. Histopathological examination showed that 84.1% of esophageal tumors were squamous cell carcinoma, and 15.9% were adenocarcinoma; 87.9% of gastric tumors were adenocarcinoma, 3.8% were malignant epithelial tumors, 5.8% were lymphoma, and 2.5% were neuroendocrine tumors; 87.5% of duodenal tumors were adenocarcinoma, and 12.5% were malignant epithelial tumors. Conclısions: Upper gastrointestinal tract malignancies are most common in the stomach, and the second most common organ is esophagus. Although rare, tumors can be seen in the duodenum.

Anahtar Kelimeler

Özofagogastroduodenoskopi, malignite

Aydın bölgesindeki üst gastrointestinal sistem malignitelerinin özellikleri

Öz

Giriş ve Amaç: Üst gastrointestinal sistem maligniteleri tüm dünyada önemli mortalite ve morbidite nedenlerindendir. Tanıda özofagogastroduodenoskopi altın standart işlemdir. Çalışmadaki amacımız endoskopi ünitemizde özofagogastroduodenoskopi işlemi ile tespit ettiğimiz ve biyopsi ile de tanısı kesinleşen üst gastrointestinal sistem malignitelerinin yaş, cinsiyet, lokalizasyon ile histopatolojik tipleri ve işlem öncesi hasta semptomları gibi bazı özelliklerini belirlemekti. Gereç ve Yöntem: Endoskopi ünitemizde özofagogastroduodenoskopi yapılan 7.688 hastadan malignite saptanan 209 (%2,71) vaka çalışmaya alındı. Bulgular: Özofagogastroduodenoskopi işleminde malignite saptanan hastaların 145’i erkek (%69,4), 64’ü kadın (%30,6) olup yaş ortalaması 62,18±12,07 yıldı. Malignitelerin %21,1’i özofagusta, %75,1’i midede ve %3,8’i duodenumda saptandı. Yapılan histopatolojik incelemede, özofagus kanserlerinin %84,1’i squamöz hücreli karsinom, %15,9’u adenokarsinom; mide kanserlerinin %87,9’u adenokarsinom, %3,8’i malign epitelyal tümör, %5,8’i lenfoma, %2,5’i nöroendokrin tümör; duodenum kanserlerinin %87,5’i adenokarsinom, %12,5’i malign epitelyal tümör olarak tespit edildi. Sonuç: Üst gastrointestinal sistem maligniteleri en sık midede, 2. sıklıkta özofagusta saptanmaktadır. Nadirde olsa duodenumda tümör görülebilmektedir.

Anahtar Kelimeler

Özofagogastroduodenoskopi, malignite

Kaynakça

• 1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
• 2. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(Suppl 8):S4-66.
• 3. Yao KA, Talamonti MS, Langella RL, et al. Primary gastrointestinal sarcomas: analysis of prognostic factors and result of surgical management. Surgery 2000;128:604-12.
• 4. Tuncer İ, Uygan İ, Kösem M, et al. Van ve çevresinde görülen üst gastrointestinal sistem kanserlerinin demografik ve histopatolojik özellikleri. Van Tıp Dergisi 2001;8:10-3.
• 5. Sarıçam T, Vardereli E, Harmancı A, et al. 1400 olguda üst gastrointestinal sistem endoskopisiyle saptanan maligniteler. Turk J Gastroenterol 1994;2:275-9.
• 6. Mayer JR. Gastrointestinal tract cancer. In: Fauci SA, Braunwald E, Hauser LS, Kasper LD, Longo DL, Jameson JL (eds). Harrison’s Principles of Internal Medicine. 18th edition. USA, McGrawHill Company 2008;764- 76.
• 7. Liu SZ, Wang B, Zhang F, et al. Incidence, survival and prevalence of esophageal and gastric cancer in linzhou city from 2003 to 2009. Asian Pac J Cancer Prev 2013;14:6031-4.
• 8. Wayman J, Forman D, Griffin SM. Monitoring the changing pattern of esophagogastric cancer: data from a UK regional cancer registry. Cancer Causes Control 2001;12:943-9.
• 9. Terry MB, Gaudet MM, Gammon MD. The epidemiology of gastric cancer. Semin Radiat Oncol 2002;12:111-27.
• 10. TC Sağlık Bakanlığı Kanser İstatistikleri. Ekim 2012.
• 11. Metlin C. Epidemiologic studies in gastric adenocarcinoma. In Douglass HO (ed). Gastric cancer. New York: Churchill Livingstone 1988;1-25.
• 12. Dökmeci G, Ulusoy E, Özdemir S, et al. Mide kanserli 69 olgunun analizi. Turk J Gastroenterol 1996;7:335-9.
• 13. Yüceyar H, Ersöz G, Çoker A, et al. Evaluation of the clinical characteristic of the patients with gastric cancer: (10 years retrospective and prospective study). T Klin Gastroenterohepatoloji 1995;6:172-6.
• 14. Yaşa MH, Coşkun A, Yükselen AV, et al. Adnan Menderes Üniversitesi Tıp Fakültesi Hastanesi endoskopi ünitesinde yapılan üst gastrointestinal sistem endoskopisindeki malignite oranları. Endoskopi Kongre Özel Sayısı. 2006;16:209.
• 15. Rakić S, Milićević MN, Kovacević P, Marković V. Increasing incidence of adenocarcinoma of the proximal stomach. Eur J Surg Oncol 1992;18:340-1.
• 16. Hosseini SN1, Mousavinasab SN, Moghimi MH, Fallah R. Delay in diagnosis and treatment of gastric cancer: from the beginning of symptoms to surgery--an Iranian study. Turk J Gastroenterol 2007;18:77-81.
• 17. Chung WC, Paik CN, Jung SH, et al. Prognostic factors associated with survival in patients with primary duodenal adenocarcinoma. Korean J Intern Med 2011;26:34-40.
• 18. Hu JX, Miao XY, Zhong DW, et al. Surgical treatment of primary duodenal adenocarcinoma. Hepatogastroenterology 2006;53:858-62.